JAMA Network Open published results of the prespecified secondary analysis of data from the PANOVA-3 trial of Novocure’s TTFields therapy concomitant with gemcitabine and nab-pac in patients with unresectable, locally advanced pancreatic adenocarcinoma: investor.novocure.com/news-releases/…
Novocure
@Novocure
We strive to extend survival in some of the most aggressive forms of cancer. Patient images reflect patient(s) health status when photographed.
228 Following 2.8K Followers 2.2K Posts
Latest posts 5
Novocure has received a Not Approvable Letter from the U.S. FDA in response to its Premarket Approval (PMA) application for its treatment for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. Read more: investor.novocure.com/news-releases/…
Novocure today reported financial results for the third quarter that ended September 30, 2026. Read more in our press release: investor.novocure.com/news-releases/…
Novocure announced its clinical trial agreement with Verastem Oncology to evaluate TTFields therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, in locally advanced pancreatic cancer: investor.novocure.com/news-releases/…
Novocure announced today that its treatment for adult patients diagnosed with unresectable locally advanced pancreatic cancer was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for concomitant use with gemcitabine and nab-paclitaxel: investor.novocure.com/news-releases/…